Welcome to our dedicated page for MBX Biosciences news (Ticker: MBX), a resource for investors and traders seeking the latest updates and insights on MBX Biosciences stock.
MBX Biosciences, Inc. (Nasdaq: MBX) is a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders, and its news flow reflects progress across multiple clinical programs and corporate initiatives. Company press releases and investor updates highlight developments from its proprietary Precision Endocrine Peptide™ (PEP™) platform, including clinical data, trial milestones, and financing activities.
News for MBX often centers on its lead candidates canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291. Coverage includes topline and follow-up results from the Phase 2 Avail™ trial of once-weekly canvuparatide in chronic hypoparathyroidism, initiation and progress of the Phase 2a STEADI™ trial of imapextide for post-bariatric hypoglycemia, and design and enrollment updates for the Phase 1 trial of MBX 4291 as a GLP-1/GIP co-agonist prodrug for obesity. MBX also issues releases on expected data readouts, planned regulatory interactions, and preparation for Phase 3 development.
Investors following MBX news will also see announcements related to public equity offerings, cash runway disclosures, and participation in major healthcare and investor conferences such as the J.P. Morgan Healthcare Conference and various cardiometabolic and obesity-focused forums. These items provide context on how the company funds its pipeline and communicates its strategy to the market.
This news page aggregates such updates so readers can track MBX’s clinical milestones, pipeline expansion in obesity, and key regulatory and financing events in one place. For those monitoring MBX stock or the broader endocrine and metabolic drug development space, the feed offers an organized view of how the company reports its progress over time.
MBX Biosciences (Nasdaq: MBX) said CEO Kent Hawryluk and CMO Sam Azoulay will present at two upcoming investor conferences in late Feb–early Mar 2026.
Events: Oppenheimer 36th Annual Healthcare Life Sciences Conference (virtual) on Feb 25, 2026 at 11:20–11:50 a.m. ET, and TD Cowen 46th Annual Health Care Conference in Boston on Mar 2, 2026 at 9:10–9:40 a.m. ET. Live webcasts and replays will be available via the company's events page and archived for about 90 days.
MBX Biosciences (Nasdaq: MBX) appointed Laurie Stelzer as an independent director and chair of the board's audit committee, effective Jan. 22, 2026. Stelzer brings over 25 years of finance and corporate governance experience, including prior CFO roles at Kailera Therapeutics, Orna Therapeutics, Mirati Therapeutics, Arena Pharmaceuticals, and Halozyme Therapeutics, and board service at multiple biotech companies. The company said the appointment strengthens financial oversight as MBX advances a catalyst-rich year that includes data from three clinical-stage programs and initiation of a Phase 3 confirmatory trial in hypoparathyroidism.
MBX Biosciences (Nasdaq: MBX) will present at the 44th Annual J.P. Morgan Healthcare Conference on Jan 13, 2026 and provide a 2026 outlook and business update.
Key clinical milestones: one-year follow-up data from the Phase 2 once-weekly canvuparatide expected Q2 2026 with Phase 3 initiation targeted Q3 2026; Phase 1 12-week data for once-monthly potential MBX 4291 expected Q4 2026; two additional obesity candidates nominated in 2026 (amycretin prodrug and GLP-1/GIP/GCGR prodrug). Preliminary unaudited cash and marketable securities were approximately $373.7M as of Dec 31, 2025, expected to fund operations into 2029.
MBX Biosciences (Nasdaq: MBX) announced that Kent Hawryluk, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026.
Format includes a company presentation and 1x1 meetings at 3:45 p.m. PT / 6:45 p.m. ET in San Francisco. A live webcast will be available via the company’s investor events page, with a replay posted approximately two hours after the events and archived for about 90 days.
MBX Biosciences (Nasdaq: MBX) announced that CEO Kent Hawryluk and CMO Sam Azoulay, M.D., will present at the 37th Annual Piper Sandler Healthcare Conference on December 2, 2025.
Presentation format: fireside chat and 1x1 meetings; time: 4:00 p.m.–4:25 p.m. ET; location: New York, NY. The presentation will be webcast live and a replay will be posted approximately two hours after the event and archived on the company website for about 90 days.
Investors can access the live webcast and replay via the events section of the MBX Biosciences investor website.
MBX Biosciences (Nasdaq: MBX) reported positive Phase 2 topline results for once-weekly canvuparatide in hypoparathyroidism, with 63% responder rate at 12 weeks and 79% at six months in the open-label extension.
The company completed an upsized public offering raising approximately $200 million and reported $391.7 million in cash, cash equivalents and marketable securities as of September 30, 2025, which management expects will fund operations into 2029. MBX highlighted planned regulatory interactions in Q1 2026 and a Phase 3 start in Q3 2026, plus ongoing MBX 4291 and imapextide trials with key readouts in 2026.
MBX Biosciences (Nasdaq: MBX) announced that CEO Kent Hawryluk and CMO Sam Azoulay, M.D., will present at four investor conferences in November 2025: Guggenheim (Nov 10, Boston), Stifel (Nov 12, New York), Jefferies (Nov 19, London) and TD Cowen virtual summit (Nov 24).
Formats include fireside chats and 1x1 meetings; listed times are local to each event. Live webcasts and replays will be available in the events section of the company investor website and archived for about 90 days.
MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, will participate in the Stifel 2025 Virtual Cardiometabolic Forum. The company's leadership, including CEO Kent Hawryluk and CMO Dr. Sam Azoulay, will engage in a fireside chat on September 30, 2025, from 10:00 AM to 10:25 AM ET.
The virtual presentation will be accessible through a live webcast on the company's investor relations website, with a replay available for approximately 90 days following the event.
MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders, has announced the pricing of its upsized public offering. The company is offering 11,108,055 shares of common stock at $18.00 per share, expecting to raise gross proceeds of $199.9 million.
The offering includes a 30-day option for underwriters to purchase up to an additional 1,666,208 shares at the public offering price, less underwriting discounts. The offering is expected to close on September 26, 2025, with J.P. Morgan, Jefferies, TD Cowen, and Guggenheim Securities serving as joint book-running managers.
MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, has announced a proposed public offering of 10 million shares of common stock. The company will also grant underwriters a 30-day option to purchase up to an additional 1.5 million shares.
The offering will be managed by J.P. Morgan, Jefferies, TD Cowen, and Guggenheim Securities as joint book-running managers, with Citizens Capital Markets and Oppenheimer & Co. serving as co-lead managers. The public offering price has not yet been determined, and the offering is subject to market conditions and SEC registration effectiveness.
FAQ
What is the current stock price of MBX Biosciences (MBX)?
What is the market cap of MBX Biosciences (MBX)?
